TY - JOUR
T1 - INO-8875, a highly selective A1 adenosine receptor agonist
T2 - Evaluation of chronotropic, dromotropic, and hemodynamic effects in rats
AU - Mor, Michal
AU - Shalev, Aryeh
AU - Dror, Shani
AU - Pikovsky, Oleg
AU - Beharier, Ofer
AU - Moran, Arie
AU - Katz, Amos
AU - Etzion, Yoram
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Selective pharmacological activation of the adenosine 1 receptor (A1R) is a promising new approach to achieve a potent block of atrioventricular (A-V)-nodal conduction without significant cardiovascular side effects. The purpose of the present study was to evaluate the cardiovascular profile of INO-8875, a highly selective A1R agonist, and to compare its properties with N -[3( R )-tetrahydrofuranyl]-6-aminopurine riboside (CVT-510), which has already been shown to induce negative dromotropic effects with minimal cardiovascular side effects in animals and in clinical studies. Dose-response experiments in the isolated hearts of rats were used to evaluate the functional selectivity of INO-8875 for the slowing of A-V-nodal conduction. Ventilated adult rats were used to study the effects of INO-8875, in vivo, on arterial blood pressure as well as on supraventricular electrophysiology. Ex vivo, INO-8875 (100 nM to 3 μM) progressively prolonged A-V- nodal conduction without reducing left ventricular function or coronary resistance. In vivo, INO-8875 up to a dose of 50 μg/kg did not reduce the carotid arterial blood pressure ( n = 4). INO-8875 (1 - 50 μg/kg) and CVT-510 (20 and 50 μg/kg) both induced a dose-dependent decrease in heart rate and atrial refractoriness, as well as slowing of A-V - nodal conduction. However, compared with CVT-510, the activity of INO-8875 was more pronounced in A-V - nodal function. INO-8875 exhibited a greater duration of action, lasting up to 2.5 hours post dosing, whereas the effects of CVT-510 dissipated over 1 hour. INO-8875 demonstrates functional properties of a highly selective A 1R agonist. INO-8875 exhibits an increased dromotropic effect and greater duration of action compared with CVT-510.
AB - Selective pharmacological activation of the adenosine 1 receptor (A1R) is a promising new approach to achieve a potent block of atrioventricular (A-V)-nodal conduction without significant cardiovascular side effects. The purpose of the present study was to evaluate the cardiovascular profile of INO-8875, a highly selective A1R agonist, and to compare its properties with N -[3( R )-tetrahydrofuranyl]-6-aminopurine riboside (CVT-510), which has already been shown to induce negative dromotropic effects with minimal cardiovascular side effects in animals and in clinical studies. Dose-response experiments in the isolated hearts of rats were used to evaluate the functional selectivity of INO-8875 for the slowing of A-V-nodal conduction. Ventilated adult rats were used to study the effects of INO-8875, in vivo, on arterial blood pressure as well as on supraventricular electrophysiology. Ex vivo, INO-8875 (100 nM to 3 μM) progressively prolonged A-V- nodal conduction without reducing left ventricular function or coronary resistance. In vivo, INO-8875 up to a dose of 50 μg/kg did not reduce the carotid arterial blood pressure ( n = 4). INO-8875 (1 - 50 μg/kg) and CVT-510 (20 and 50 μg/kg) both induced a dose-dependent decrease in heart rate and atrial refractoriness, as well as slowing of A-V - nodal conduction. However, compared with CVT-510, the activity of INO-8875 was more pronounced in A-V - nodal function. INO-8875 exhibited a greater duration of action, lasting up to 2.5 hours post dosing, whereas the effects of CVT-510 dissipated over 1 hour. INO-8875 demonstrates functional properties of a highly selective A 1R agonist. INO-8875 exhibits an increased dromotropic effect and greater duration of action compared with CVT-510.
UR - http://www.scopus.com/inward/record.url?scp=84871694690&partnerID=8YFLogxK
U2 - 10.1124/jpet.112.200873
DO - 10.1124/jpet.112.200873
M3 - Article
AN - SCOPUS:84871694690
SN - 0022-3565
VL - 344
SP - 59
EP - 67
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 1
ER -